Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Lipo3K Transfection Reagent for ccRCC Studies
2026-09-26
Build clearer experiments on OTUD3–SLC7A11 signaling and sunitinib resistance with a low-toxicity lipid delivery workflow. Lipo3K supports plasmid, siRNA, and co-transfection designs, with practical timing guidance for gene-expression and RNA-interference readouts.
Belinostat (PXD101): Cancer Research Workflows
2026-09-25
Belinostat (PXD101) supports controlled studies of HDAC inhibition, cell-cycle effects, and cancer-cell response in bladder and prostate models. This workflow connects practical assay design to emerging HCC spliceosome research while clearly distinguishing established product data from hypotheses that need testing.
Pexidartinib (PLX3397): CSF1R Research Guide
2026-09-25
Pexidartinib (PLX3397) is an orally bioavailable, ATP-competitive inhibitor used to investigate CSF1R-mediated signaling and macrophage biology. Its product-reported activity supports experimental study of tumor microenvironment macrophage modulation, but it should not be treated as a validated SPP1-specific inhibitor.
From Spatial IL-6 Biology to JAK1/2 Experiments
2026-09-24
Spatial proteomics is bringing cytokine biology into tissue context. Learn how Baricitinib (LY3009104) can test JAK1/2 dependence in compartment-aware inflammation studies—without mistaking a mechanistic hypothesis for evidence of efficacy in primary sclerosing cholangitis.
Cabozantinib (XL184) for RCC Adaptation Studies
2026-09-24
Use Cabozantinib to compare early kinase suppression with the signaling and motility changes that emerge during prolonged exposure in renal cell carcinoma models. This practical workflow combines phosphoproteomics, migration, and invasion readouts while distinguishing product specifications from study-specific findings and experimental recommendations.
Bifidobacterium, FMT, and PET in HE Rats
2026-09-23
This study used [18F]PBR146 PET/CT to compare Bifidobacterium and fecal microbiota transplantation in rats with bile duct ligation-induced chronic hepatic encephalopathy. Global brain uptake and several behavioral and cytokine measures did not differ significantly, but regional imaging findings supported a neuroinflammation-reducing effect of Bifidobacterium that was not observed with FMT.
Aprotinin Workflows for Protease-Controlled Research
2026-09-23
Aprotinin enables controlled, reversible suppression of trypsin, plasmin, and kallikrein in biochemical, inflammatory, and cardiovascular research models. This guide combines practical dosing logic, sample-handling workflows, GRO-seq-inspired quality controls, and troubleshooting strategies for more reproducible experiments.
Localized BDNF Release in NMJ Assembly
2026-09-22
The reference study shows that skeletal muscle-derived BDNF is trafficked to actin-rich podosome-like structures, where calcium-dependent, spatially restricted release supports the earliest stages of neuromuscular junction assembly. Its combination of live imaging, targeted perturbations, and muscle-specific knockout experiments links BDNF localization and proteolytic processing to aneural and nerve-induced acetylcholine receptor clustering.
BMS-777607: From MET Biology to Translational Models
2026-09-22
A mechanism-first guide to using BMS-777607 as a selective c-Met inhibitor across cancer metastasis models, MET-family biology, and exploratory hiPSC-derived platelet research.
Reserpine (N1867): Practical Lab Workflow
2026-09-21
Reserpine (SKU N1867) provides a high-purity, characterized research reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide covers identity checks, DMSO preparation, storage, and troubleshooting while clarifying that the product is for research use only, not diagnostic, clinical, medical, or veterinary applications.
Firefly Luciferase mRNA: Assay Workflow
2026-09-21
Build more interpretable transfection, gene expression, cell viability, and imaging studies with a chemically optimized bioluminescent reporter. This workflow connects practical handling of Firefly Luciferase mRNA with delivery benchmarking and translational mRNA research.
Nutlin-3a and the Next Logic of p53 Translation
2026-09-20
Nutlin-3a offers a precise way to interrogate MDM2–p53 biology while opening a translational conversation about ferroptosis, migration, and treatment strategy in glioblastoma. This article connects target engagement with experimental design, model selection, and clinically relevant decision points.
FITC Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-09-19
This fluorescein-conjugated secondary antibody provides fluorescent detection of mouse IgG primary antibodies in immunofluorescence, microscopy, and flow cytometry workflows. It is intended for research assay development and optimization, not as a standalone reagent for detecting non-mouse immunoglobulins or as evidence of a validated clinical diagnostic procedure.
BMPSB4 Activates Autophagy in Corticotroph PitNETs
2026-09-18
A 2024 study identifies BMPSB4 as a pharmacological agonist of deficient BMP4 signaling in corticotroph pituitary neuroendocrine tumors. Using transcriptomic, imaging, cellular, and animal-model evidence, the authors link BMP4/SMAD1/5/9 activation to autophagy-mediated tumor suppression and reduced ACTH and corticosterone output.
Sodium Ascorbate: From ROS Biology to Translation
2026-09-18
A translational perspective on how Sodium Ascorbate can support reproducible ROS-driven cancer research, while biomarker-led models such as circulating GPNMB illustrate the requirements for moving from tumor-cell phenotypes toward precision study design.
8584 records 6/573 page Previous Next First page 上5页 678910 下5页 Last page